Eli Lilly and Company (BMV:LLY)

Market Cap	10.41T
Revenue (ttm)	1.00T
Net Income (ttm)	260.24B
Shares Out	n/a
EPS (ttm)	288.39
PE Ratio	40.00
Forward PE	22.88
Dividend	111.06 (0.95%)
Ex-Dividend Date	May 16, 2025

Volume	3,497
Average Volume	1,714
Open	12,139
Previous Close	12,043
Day's Range	11,630 - 12,139
52-Week Range	11,630 - 19,261
Beta	0.44
RSI	23.90
Earnings Date	Aug 7, 2025

About Accolade

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.